Jansen underscores the need for urologists to go beyond symptom treatment and focus on identifying root causes of testosterone deficiency.

Jack Andrews, MD; Alicia Morgans, MD, MPH; and Ashley Ross MD, PhD, discuss how trial design, inclusion criteria, and end points like radiographic progression-free survival vs overall survival impact ...

Data from the phase 2 EXTEND trial showed that the addition of metastasis-directed therapy to ADT improved measures of systemic disease control.

The phase 1/2 CaRe PC trial (NCT06056791) assessing INKmune in patients with metastatic castration-resistant prostate cancer (mCRPC) has met its primary and secondary end points, INmune Bio reported ...

Key Takeaways ArteraAI Prostate, an AI tool, assists in risk-based decisions for localized prostate cancer by analyzing biopsy images to predict metastasis and mortality risks. The FDA breakthrough ...

Key Takeaways Botulinum toxin with an anti-nausea patch reduces salivary gland toxicity in PSMA-directed radiopharmaceutical therapy for metastatic prostate cancer. A 30% reduction in PSMA uptake by ...

David Stanley, MD, FACS, discusses current trends and unmet needs in the treatment of patients with kidney stones.

Howard B. Goldman, MD, FACS, discusses innovations such as tibial nerve stimulation devices, pudendal nerve targeting, and alternative stimulation frequencies.

Key Takeaways Mitomycin for intravesical solution is the first FDA-approved treatment for recurrent LG-IR-NMIBC, with availability expected by July 2025. The phase 3 ENVISION trial demonstrated a 78% ...

The FDA has authorized an Expanded Access Program (NCT06956547) for use of nogapendekin alfa inbakicept-pmln (NAI; Anktiva) to manage lymphopenia in adult patients with refractory or relapsed solid ...

In 2015, 1245 patients had prostate cancer and had also initiated a GLP-1 or GIP/GLP-1 receptor agonist compared with 69,808 patients in 2024.

Initial results from the phase 3 ARCHES trial (NCT02677896) showed an overall survival (OS) benefit with enzalutamide plus androgen deprivation therapy (ADT) vs ADT alone in patients with metastatic ...